An NCI-designated Comprehensive Cancer Center
Assistant Professor, Department of Hematologic Malignancies Translational Science

Ling Li, Ph.D.

Associate Professor, Department of Hematologic Malignancies Translational Science
Research Focus
  • Leukemia stem cells
  • Acute myeloid leukemia
  • Chronic myeloid leukemia

Research Teams

  • Hematologic Malignancies Program (CCC)
  • Hematologic Malignancies Translational Science
  • Hematology & Hematopoietic Cell Transplantation
  • Leukemia Research
  • Stem Cell Transplantation Research


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

Peer-reviewed Publications (Selected List)

  • Li L, Bhatia R. Role of SIRT1 in the Growth and Regulation of Normal Hematopoietic and Leukemia Stem Cells. (2015). Current Opinion in Hematology. 22(4):324-329. [PMCID:PMC4482757]
  • Wang L, Li L, et al. MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors.  Blood.2015;125(8):1302-13. PMID: 25515961
  • Li L, Osdal T, Ho Y, et al. SIRT1 activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells. (2014). Cell Stem Cell. 15(4), 431-446. [PMCID: PMC430539]
  • Cook AM, Li L, Ho Y, Lin A, Li L, et al. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. Blood. 2014;123:2826-37.
  • Tian W, Deng Y, Li L, et al. Honokiol synergizes chemotherapy drugs in multidrug resistant breast cancer cells via enhanced apoptosis and additional programmed necrotic death. Int J Oncol. 2013;42:721-32.
  • Li L, Wang L, Li L, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell. 2012; 21(2), 266–281.(Featured Article)
  • Yuan H*, Wang Z*, Li L*, et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood. 2012; 119(8), 1904-1914  (*equal contribution, co-first author)
  • Han W, Xie J, Li L, Liu Z, Hu X. Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis. 2009; 14(5), 674-686.
  • Chen W, Zhao Z, Li L, et al. Hispolon induces apoptosis in human gastric cancer cells through a ROS-mediated mitochondrial pathway. Free Radical Biology & Medicine. 2008; 45(1), 60–72.
  • Li L, Pan Q, Han W, Liu Z, Li L, Hu X. Schisandrin B Prevents Doxorubicin-induced Cardiotoxicity via Enhancing Glutathione Redox Cycling. Clin Cancer Res. 2007; 13(22 Pt 1), 6753-6760.
  • Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y, Luo J, Hu X. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther. 2007; 6(5), 1641-1649.
  • Li L, Han W, Gu Y, Qiu S, Lu Q, Jin J, Luo J, Hu X. Honokiol Induces a Necrotic Cell Death through the Mitochondrial Permeability Transition Pore. Cancer Research. 2007; 67(10), 4894-4903.
  • Li L, Lu Q, Shen Y, Hu X. Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem Pharmacol. 2006; 71(5), 584-595.

Invited Reviews

  • Li L, Bhatia R.The controversial role of Sirtuins in tumorigenesis - SIRT7 joins the debate. Cell Research. 2013; 23(1), 10–12.
  • Li L, Bhatia R. Stem Cell Quiescence. Clinical Cancer Research. 2011; 17(15), 4936-4941.
  • Hu X, Han W, Li L. Targeting the Weak Point of Cancer by Induction of Necroptosis. Autophagy. 2007; 3(5), 490-492.

Selected Conference Presentations

  • Oral Presentation in 2009 ASH (American Society of Hematology) annual meeting. Title: Role of the SIRT1 Deacetylase in Survival and Imatinib Resistance of CML CD34+ Progenitors. Blood. vol. 114, pp. A189, 2009.
  • Oral Presentation in 2010 ESH international conference Chronic Myeloid Leukemia-Biological Basis of Therapy. Title: SIRT1 inhibition induces apoptosis in human CML progenitors.
  • Oral Presentation in 2010 ASH  annual meeting. Title: SIRT1 inhibition induces apoptosis in human CML progenitors by enhancing p53 acetylation and activation. Blood. vol. 116, pp. A200, 2010.
  • Oral Presentation in 2011 ASH  annual meeting. Title: Pharmacological inhibition of the stress-related deacetylase SIRT1 with the small molecule inhibitor Tenovin-6 enhances eradication of CML LSC in combination with TKI treatment. Blood. vol.118, pp. A448, 2011.
  • Poster Presentation in 2012 ASH  annual meeting. Title: FLT3-ITD+ AML Stem/Progenitor Cells Demonstrate Increased SIRT1 Expression and Enhanced Sensitivity to SIRT1 Inhibition. Blood. vol.120, pp. A1368, 2012.
  • Poster Presentation in 2013 ASH  annual meeting. Title: Pharmacological Inhibition Of The SIRT1 Deacetylase With The Small Molecule Inhibitor Tenovin-6 Enhances Ablation Of FLT3-ITD+ LSC In Combination With TKI Treatment. Blood. vol.122, pp. A2685, 2013.
  • Poster Presentation in 2010 ASH  annual meeting. L Wang, L Li, et al.Title: MicroRNA-486-5p Targets Foxo1 and Regulates Human Hematopoietic Stem Cell Proliferation and Erythroid Differentiation. Blood. vol. 116, pp. A3871, 2010.
  • Poster Presentation in 2011 ASH  annual meeting. L Wang, L Li, et al.Title: Role of MicroRNA-486-5p Overexpression In CML CD34+ Cells In Modulating BCR-ABL Mediated Hematopoietic Stem/Progenitor Cell Transformation and Imatinib Sensitivity. Blood. vol. 118, pp. A1667, 2011.
  • Poster Presentation in 2014 ASH annual meeting. Duchartre Y,  L Li, et al. Increased p53 Acetylation By SIRT1 Inhibition Is Required for Optimal Activation of p53 Activity and Significantly Enhances the Ability of HDM2 Inhibitors to Target CML LSC. Blood. 2014; vol.124.pp. A4521.

Complete list of work on published work at:

In The News